High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)

The High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional) opportunity, with the funding number RFA-DA-25-060, seeks to support transformative and collaborative research projects addressing the intersection of HIV and substance use. It targets research that could introduce novel directions in HIV/AIDS studies or open new paths for prevention, treatment, and cure among people using addictive substances. The program emphasizes interdisciplinary and integrative approaches that combine diverse expertise across disciplines to achieve significant advancements in the field. Research areas include basic science, epidemiology, clinical interventions, and implementation science, with a focus on understanding HIV transmission, disease progression, and associated health outcomes among those with substance use disorders (SUDs). Eligible teams must consist of three to six Principal Investigators (PD/PIs), each contributing a distinct yet essential expertise toward a singular transformative goal that could not be addressed by individual efforts alone. The research must be innovative and ambitious, aiming for significant outcomes within a five-year period. Applicants should present preliminary data, a well-structured research plan, and evidence of an interdisciplinary approach capable of addressing complex issues at the intersection of HIV and substance use. Studies focusing solely on existing research program extensions, technological development, or standard clinical trials without broader transformative aims will not be considered responsive to this funding opportunity. Applicants are required to submit a Plan for Enhancing Diverse Perspectives (PEDP), detailing strategies for fostering inclusivity and diverse scientific viewpoints in the proposed research. This plan, along with team management, timeline, benchmarks for success, and an organization chart, must be included in the application package. The program aims to ensure effective collaboration and knowledge transfer across the team while promoting the inclusion of diverse researchers and viewpoints. Funding for this opportunity will be available for one to two awards annually, with a maximum budget of $1.5 million per fiscal year in direct costs over a five-year period. Eligible applicants include higher education institutions, nonprofits, state and local governments, and tribal organizations. Foreign organizations are not eligible, though foreign components of U.S.-based projects may be included. The next application due date is August 15, 2024, with subsequent review and award cycles occurring biannually through February 2027. Applications must be submitted through Grants.gov, using one of the designated submission platforms. Potential applicants are encouraged to consult with NIDA program staff to ensure alignment with programmatic goals and to discuss the relevance of their proposed projects. For further information, the full funding announcement and application guidelines are available via the NIH Grants Guide.